國家衛生研究院 NHRI:Item 3990099045/12150
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 909087      在线人数 : 900
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12150


    题名: Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and nonalcoholic fatty liver disease in mice
    作者: Chiang, H;Lee, JC;Huang, HC;Huang, H;Liu, HK;Huang, C
    贡献者: Institute of Biotechnology and Pharmaceutical Research
    摘要: BACKGROUND AND PURPOSE: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is closely related to metabolic diseases such as obesity and diabetes. Despite an accumulating number of studies, no pharmacotherapy that targets NAFLD has received general approval for clinical use. EXPERIMENTAL APPROACH: Sodium glucose cotransporter 2 (SGLT2) inhibition is a promising approach to treat diabetes, obesity, and associated metabolic disorders. In this study, we investigated the effect of a novel SGLT2 inhibitor, NGI001, on NAFLD and obesity-associated metabolic symptoms in high fat diet (HFD)-induced obese mice. KEY RESULTS: Delayed intervention with NGI001 protected against body weight gain, hyperglycemia, hyperlipidemia and hyperinsulinemia, compared with HFD alone. Adipocyte hypertrophy was prevented by administering NGI001. NGI001 inhibited impaired glucose metabolism and regulated the secretion of adipokines associated with insulin resistance. In addition, NGI001 supplementation suppressed hepatic lipid accumulation and inflammation, and had little impact on kidney function. In-depth investigations showed NGI001 ameliorated fat deposition and increased AMPK phosphorylation, resulting in phosphorylation of its major downstream target, ACC, in human hepatocytes, HuS-E/2 cells. This cascade ultimately led to the downregulation of downstream fatty acid synthesis-related molecules and the upregulation of downstream beta oxidation-associated molecules. Surprisingly, NGI001 decreased gene and protein expression of SGLT1 and SGLT2 and glucose uptake in oleic acid-treated HuS-E/2 cells. CONCLUSION AND IMPLICATIONS: Our findings suggest the therapeutic potential of the novel SGLT2 inhibitor, NGI001, to attenuate or delay the onset of diet-induced metabolic diseases and NAFLD.
    日期: 2020-01-01
    關聯: British Journal of Pharmacology. 2020 Jan 1;177(2):239-253.
    Link to: http://dx.doi.org/10.1111/bph.14859
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0007-1188&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000495923400001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85074984198
    显示于类别:[李靜琪] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB31497874.pdf9935KbAdobe PDF290检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈